How do treatments for mood and anxiety disorders derived from psilocybin exert their effects in the brain?
Beckley Psytech has dosed the first participant in its Phase 1 single-ascending dose (SAD) study of ELE-101 – a novel intravenous formulation of psilocin – with...
Apex Labs has been granted approval by Health Canada for the first North American take-home multi-dose psilocybin clinical trial evaluating the safety and efficacy of APEX-52...
New data has revealed that a single 25mg dose of COMPASS Pathways’ COMP360 psilocybin in combination with psychological support had a significant impact in reducing symptoms...
The University of Guelph (UoG) has announced that it is one of the first universities to be granted a licence by Health Canada to cultivate psychedelic...
Clairvoyant has received regulatory approval for its Phase 2 trial investigating psilocybin for the treatment of alcohol use disorder (AUD).
LOVE Pharma’s trial will be exploring psilocybin-assisted therapy for cannabis use disorder (CUD), with Johns Hopkins University School of Medicine’s Dr Albert Garcia-Romeu serving as head...
Silo Wellness has confirmed it has acquired Dyscovry Science – a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives, targeting irritable bowel...
A wholly-owned subsidiary of HYTN Innovations Inc.,
Numinus Wellness is developing an innovative method of delivery for psilocybin in clinical trials and research.